To test this hypothesis, we extracted genomic DNA from one peripheral blood and 25 bone marrow samples of AML patients with t(8;21) from the University Medical Centers Freiburg, Germany and Nijmegen, The Netherlands. All patients had provided ethic board approved informed consent. The blast count in the peripheral blood sample was 35% and in bone marrow samples 470% in the majority of samples (range: 25-90%). In addition, to explore the mutation status in a homogeneous blast population, we investigated two AML cell lines bearing t(8;21), Kasumi-1 and SKNO. We amplified a 268-bp fragment of AML1-ETO encompassing the entire coding region of the NHR4 domain (aa658-707) (Table 1, Figure 1 ) and applied bidirectional sequencing (GATC Biotech, Konstanz, Germany). However, we identified no mutations within the NHR4 coding genomic sequence of these AML patients or the two cell lines. With the limitations of a cohort of 26 patient samples, we conclude that mutations within the NHR4 domain of AML1-ETO are probably a very infrequent event in patients with t(8;21). Our results also support the idea that in vivo, other mechanisms than NHR4 mutations, for example, a dysfunctional SON protein might be a reason for hampered interaction of AML1-ETO and SON.
Identification of activated Tnk1 kinase in Hodgkin's lymphoma Protein tyrosine kinases are important regulators of intracellular signal-transduction pathways mediating cellular proliferation, survival and development. The activity of these kinases is normally tightly regulated, and constitutive activation of tyrosine kinases by acquired somatic mutation contributes to oncogenic transformation in many types of tumors. Hodgkin's lymphoma (HL) is one of the most common lymphomas in the world, characterized by the presence of Reed-Sternberg cells. ReedSternberg cells show deregulation of multiple signaling pathways and transcription factors, including receptor tyrosine kinases, JAK/STAT and nuclear factor-kB. 1 Dysregulation of STAT pathway has been associated with leukemogenesis, and phosphorylation of STAT5 is a reliable surrogate marker for tyrosine kinase activity. To identify novel activated tyrosine kinases that confer constitutive phosphorylation of STAT5, we first screened human HL cell lines for evidence of STAT5 activation by immunoblot analysis, using a Letters to the Editor phospho-STAT5-specific antibody. STAT5 was constitutively tyrosine phosphorylated in a HL cell line L540 ( Figure 1a ) that was established from the bone marrow of an adult female patient with nodular sclerosis. 2 Then, we used a discovery platform consisting of immunoaffinity profiling coupled to mass spectrometry (PhosphoScan) that identifies large numbers of tyrosine phosphorylated proteins, including active kinases. 3 Whole cell lysates were digested with trypsin, phosphopeptides were immunoprecipitated with phosphotyrosine antibody (pY-100), and resultant immunoprecipitates were analyzed by LC-MS/MS mass spectrometry. Duplicate runs of LC-MS/MS analysis on an LTQ ion trap mass spectrometer identified 733 phosphotyrosine sites in 554 tyrosine phosphorylated proteins in L540 cells (Supplementary Table 1 Letters to the Editor not shown). TNK1 is a member of the ACK family of nonreceptor tyrosine kinases and was originally cloned from CD34 þ /LinÀ/CD38À hematopoietic progenitor cells. 4 On the basis of these data, Tnk1 could be aberrantly activated in L540 cells. Western blot analysis using an antibody raised against Y277 of Tnk1 confirmed the phosphorylation of Tnk1 at this site ( Figure 1b) . Moreover, we observed a 60 kDa truncated form of Tnk1 in L540, as compared with the wild-type Tnk1 in K562 cells (Figure 1b) . To determine whether a chimeric TNK1 transcript was present, we performed both 5 0 and 3 0 RACE on the sequence encoding the kinase domain of Tnk1. Although sequence analysis of 5 0 RACE product revealed wild-type Tnk1 sequence (data not shown), 3 0 RACE product showed that 5 0 part of Tnk1 including the kinase domain was fused to sequences composed of 31 bp from 5 0 untranslated region, complete exon 2 and the first 52 bp of exon 3 of chromosome 17 open reading frame 61 (C17ORF61) gene (Figure 1c) , resulting from paracentric inversion (17)(p13.1). As C17ORF61 gene contains four exons, the C17orf61 moiety in this fusion is not in frame. Thus, the activation of truncated Tnk1 could be due to removal of its C-terminal inhibitory sequences. The expression of this truncated Tnk1 transcript was further confirmed by reverse transcription-PCR (Tnk1-F8: 5 0 -TGTGTGAGGGATGTCACAGA ACCA; C17orf61-R3: 5 0 -TTGTTGGCCTTGTCAAACAGCTCC) (Figure 1d ). However, wild-type TNK1 was not expressed in L540 cell line (Tnk1-F6: 5 0 -GCACCATCAAGGTGGCTGACTT; Tnk1-R9: 5 0 -GCGCATCCCAAAGATTTGCCTTCT). Although the signaling pathways regulated by TNK1 are largely unknown, it was shown to have a negative regulatory role in the Ras-Raf1-MAPK pathway. Tnk1 knockout mice have been shown to develop spontaneous tumors, 5 suggesting a role as a tumor suppressor gene. In addition, activation of TNK1 enables tumor necrosis factor-a-induced apoptosis by preventing activation of nuclear factor-kB. 6 To find out whether the truncated Tnk1 kinase contributes to the growth and viability of L540 cells, expression of the Tnk1 kinase was downregulated with specific small interfering RNA by electroporation. 7 Western blot analysis revealed that expression of the Tnk1 was specifically and significantly reduced 48 h after transfection of Tnk1 small interfering RNA, accompanied by a decrease in the global tyrosine phosphorylation assessed by pY-100 antibody (Figure 2a ). In addition, phosphorylation of STAT5, STAT3 and AKT was also dramatically reduced (Figure 2b) . Downregulation of Tnk1 resulted in inhibition of cell growth and proliferation (Figure 2c) , accompanied by an increase in apoptosis measured by cleaved PARP antibody (Figure 2d) . Thus, our results suggest that the truncated Tnk1 kinase is essential for the growth and proliferation of L540 cells. The oncogenecity of Tnk1 kinase was further supported by a recent retroviral insertional mutagenesis screening that identified Tnk1 as a potential oncogene. 8 So, whether Tnk1 is a tumor suppressor or an oncogene may depend on its cellular context.
In conclusion, we identified novel constitutively activated alleles of the Tnk1 kinase in the HL cell line L540. Because Tnk1 appears to drive proliferation and survival of the cells, L540 cell lines represents a valuable in vitro model for screening Tnk1 inhibitors. L540 cell line also provides a unique model for studying Tnk1-mediated signaling pathways in HL, as well as Letters to the Editor other human disorders associated with deregulated Tnk1 kinase activity. 
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Acute lymphoblastic leukemia (ALL) is a clonal expansion of cells committed into the lymphoid lineage, and, thus, ALL cells express cell surface antigens that are present at discrete stages of normal lymphoid precursors. It has been reported that 5-30% of childhood ALLs express so-called myeloid antigens such as CD11b, CD13, CD14, CD15 and CD33. 1, 2 As representatively shown in reference no. 1, studies in the early 1990s showed the association of myeloid antigen expression with poor prognosis in childhood ALL. Although subsequent studies, as representatively shown in reference no. 2, failed to confirm the prognostic significance of myeloid antigen expression in childhood ALLs that were treated with intensified chemotherapeutic regimens, a later study by the BFM group showed that expression of CD33, but not other myeloid antigens, was an independent poor prognostic factor for childhood B-precursor ALL. 3 The expression of these myeloid antigens on ALL cells has generally been speculated to reflect either misprogramming of differentiation or neoplastic transformation of the particular lymphoid progenitors that co-express myeloid antigens. However, the precise mechanism of myeloid antigen expression in ALL cells largely remains unclarified. t(17;19)-positive ALL has unique characteristics such as frequent presentation of intravascular coagulopathy and hypercalcemia, and has an extremely poor prognosis. 4 Among seven t(17;19)-ALL cases accumulated in Japan, six cases (85.7%) showed surface CD33 expression (Figures 1a and b) , whereas only two cases (28.6%) showed CD13 expression. In addition, 3 of 4 t(17;19)-ALL cell lines (Endo-kun, YCUB-2, and UOC-B1) moderately expressed CD33 (Figure 1c) , whereas none of these lines expressed surface CD13. Real-time RT-PCR revealed that CD33 mRNA expression levels in ALL cell lines correlated with CD33 expression on the cell surface (Figure 1d) , and that CD33 mRNA expression levels in t(17;19)-ALL lines were relatively high in comparison with other types of ALL, with one exception (HAL-01).
In t(17;19)-ALL, the transactivation domain of E2A is fused to the DNA-binding and dimerization domain (bZIP) of HLF, 5 resulting in expression of E2A-HLF fusion transcription factor. Interestingly, HAL-01 cells express E2A-HLF protein with a point mutation causing substitution of isoleucine (I)-526 to phenylalanine (F) in the bZIP domain of HLF that considerably reduces the DNA-binding activity of E2A-HLF, suggesting that intact E2A-HLF transactivates transcription of CD33. To test this, E2A-HLF was inducibly expressed using a Zn-inducible vector in Reh, a CD33-negative pre-B ALL line that expresses CD33 mRNA at an approximately 100-fold lower level than UOC-B1 (Figure 1d ). In two independent clones (Reh E2A-HLF no. 5 and no. 8), both of which expressed E2A-HLF induced by Zn at an equivalent level to that in UOC-B1 (Figure 2a, lanes 5 and 7) , the levels of CD33 mRNA were over 100-fold higher than that in wild-type Reh (Figure 2b ) and cell surface expression of CD33 became detectable (Figure 2c) . Induction of CD33 mRNA by more than 100-fold was also observed in 697 E2A-HLF cells (Figure 2e ), in which E2A-HLF was induced by Zn at an equivalent level to that in UOC-B1 (Figure 2d) . A reporter assay of the CD33 gene promoter using 697 E2A-HLF cells revealed that the promoter activity of the À839/ þ 508 fragment, which was reported to be active in myeloid cells, 6 was significantly upregulated by Zn (Figure 2f ), indicating that E2A-HLF upregulates transcription of the CD33 gene. It was confirmed that introduction of E2A-HLF induced CD33 mRNA and cell surface protein expression in Nalm6, a B-precursor ALL cell line (Supplementary Figure S1) . It is interesting to note that in Reh E2A-HLF no. 8, neither cell surface expression of CD11b, CD13, CD14 and CD15 (Supplementary Figure S2a) nor cytoplasmic expression of myelo-peroxidase (MPO) (data not shown) was upregulated in the presence of zinc. Although cell surface expression of CD10 and HLA-DR was moderately downregulated, cell surface expression of B-cell-related antigens including CD19, CD22 and CD24 was maintained (Supplementary Figure S2b) . These observations indicate that E2A-HLF is responsible for ectopic CD33 expression in t(17;19)-ALL cells. To the best of our knowledge, this is the first report showing that a fusion protein derived from chromosomal translocation is involved in expression of myeloid antigens on ALL cells.
To further clarify the mechanism by which E2A-HLF induces CD33 gene expression, a panel of E2A-HLF mutants (DAD1/ DLH, IF, BX) was tested (Supplementary Figure S3a) . Each mutant was expressed in Reh cells induced by Zn at an almost equivalent level to that of intact E2A-HLF in UOC-B1 (Supplementary Figure S3b) . EMSA using an oligonucleotide containing the consensus binding sequence of HLF (HLF-CS) as a probe (Supplementary Figure S3c) confirmed the similar DNAbinding activity of DAD1/DLH, which lacks two transactivation domains of E2A, but has the intact bZIP domain, compared with that of E2A-HLF. However, both the IF mutant, which carries a
